Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit ConstipationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the gut metagenome of patients with slow transit constipation (STC), a common gastrointestinal diagnosis. The goal was to identify microbial and metabolic differences that could serve as diagnostic or predictive biomarkers.
How was it studied?
A quantitative metagenomics study was conducted in 118 Chinese individuals. A discovery cohort of 50 STC patients and 40 healthy controls was analyzed, then findings were checked in a validation cohort of 16 patients and 12 healthy controls.
What did they find?
The intestinal microbiome of STC patients differed significantly from healthy individuals at the phylum, genus, and species level. STC patients had markedly higher Alistipes and Eubacterium and lower abundance of multiple Roseburia species. Gene expression and KEGG pathway enrichment, including fatty acid biosynthesis, butanoate metabolism, and methane metabolism, also differed substantially between groups.
Why it matters
These microbiome and metabolite differences may serve as valuable biomarkers for slow transit constipation. The authors suggest microbiome alteration may drive constipation through changes in microbial-derived metabolites, informing future microbial drug development.